Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
OTCMKTS:CYDY

CytoDyn Q1 2027 Earnings Results & Report

CytoDyn logo
$0.25 +0.02 (+9.51%)
As of 10/19/2026 03:59 PM Eastern

CytoDyn beat analyst earnings expectations in its Q1 2027 results, released October 14, 2026. The company reported EPS of -$0.01 versus the -$0.05 consensus estimate.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q1 2027
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

CytoDyn EPS Results

Actual EPS
-$0.01
Consensus EPS
-$0.05
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

CytoDyn Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

CytoDyn's Q1 2027 Quarterly reportQuarterly report
(10-Q)

CytoDyn Q1 2027 Earnings FAQ

CytoDyn (OTCMKTS:CYDY) reported earnings of -$0.01 per share for Q1 2027, beating the consensus estimate of -$0.05. The report was announced on Wednesday, October 14, 2026.

CytoDyn Earnings Headlines

CytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities Transcript
October 19 at 8:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4955334-cytodyn-inc-cydy-discusses-latest-scientific-clinical-operational-and-financial-progress-and
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
October 19 at 5:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/19/3383916/19782/en/cytodyn-appoints-robert-e-hoffman-as-chief-executive-officer.html
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
 |  Weiss Ratings (Ad)
CytoDyn to Host Investor Webcast
October 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/15/3381630/19782/en/cytodyn-to-host-investor-webcast.html
CytoDyn Inc. Reports Earnings Results for the First Quarter Ended August 31, 2026
October 14, 2026  |  marketscreener.comM
CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
October 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/08/3377264/19782/en/cytodyn-to-present-updated-data-from-phase-2-clover-clinical-study-at-esmo-congress-2026.html
See More CytoDyn Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CytoDyn? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CytoDyn and other key companies, straight to your email.

About CytoDyn

CytoDyn (OTCMKTS:CYDY) is a biotechnology company focused on the development of leronlimab, an investigational monoclonal antibody that targets CCR5, a receptor involved in immune-cell signaling and the movement of certain cells through the body. The company’s research has explored potential applications in infectious diseases, oncology and inflammatory conditions.

Leronlimab, also known as PRO 140, has been studied primarily as a potential treatment for HIV infection, including in combination with existing antiretroviral therapies. CytoDyn has also evaluated the drug in investigational programs involving cancer and other diseases. Leronlimab is not an approved product, and the company’s programs remain subject to clinical, regulatory and scientific development requirements.

CytoDyn is headquartered in Vancouver, Washington, and has historically operated as a development-stage biotechnology company rather than a commercial pharmaceutical business. The company’s activities have centered on clinical research, regulatory engagement and potential partnering related to leronlimab. Dr. Jacob Lalezari has served in a senior leadership role, including as chief executive officer, and has been associated with the company’s HIV development efforts.

View CytoDyn Profile
Earnings Tools